PP
ISEE

PDT Partners’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

PDT Partners’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-19,249
Closed -$98K – 896
2020
Q2 		$98K Sell
19,249
-51,551
-73% -$215K 0.01% 632
2020
Q1 		$244K Buy
+70,800
New +$414K 0.02% 518

Other funds holding ISEE

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

PDT Partners's ISEE Position: Q3 2020 in Review

PDT Partners sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2020, closing a stake of 19,249 shares — an estimated $98K sold.

PDT Partners first reported a position in ISEE in Q1 2020 and held it in 2 quarters. The position peaked at $244K in Q1 2020. 100 funds tracked by Wall St. Rank hold ISEE as of Q3 2020.

  • PDT Partners reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • PDT Partners sold 19,249 IVERIC bio, Inc. Common Stock shares in Q3 2020, an estimated $98K.
  • PDT Partners first reported a position in IVERIC bio, Inc. Common Stock in Q1 2020 and held it in 2 quarters.
  • PDT Partners's IVERIC bio, Inc. Common Stock position peaked at $244K in Q1 2020.
  • 100 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2020.

Based on PDT Partners's 13F filing for Q3 2020, filed 16 Nov 2020.